Cancer Diagnosis & Treatment

Biography

Sanjay K Srivastava is a Professor of Biomedical Sciences at Texas Tech University Health Sciences Center (TTUHSC), Amarillo, Texas, specializing in cancer biology and nutritional chemoprevention. Prior to his arrival at TTUHSC in 2007, Dr. Srivastava served as an Assistant Professor in the Department of Pharmacology, University of Pittsburgh School of Medicine and was a full member of the University of Pittsburgh Cancer Institute. He also served as Research Scientist at Mercy Cancer Institute, Mercy Hospital of Pittsburgh and did his post-doc from University of Texas Medical Branch at Galveston, Texas. Dr. Srivastava received a B.S. in Physics, Chemistry & Math and a M.S. in Biochemistry from Lucknow University, India. His Ph.D. is in Biochemistry and Toxicology from Industrial Toxicology Research Center, Lucknow and Kanpur University, Kanpur, India. His research interests include cancer biology, chemoprevention of cancers by naturally occurring nutritional agents, chemical carcinogenesis and cell signaling. Dr. Srivastava is currently funded by two R01 grants from the National Cancer Institute, NIH. He has authored more than 100 research papers and book chapters and is a member of the American Association for Cancer Research, Society of Toxicology and AAPS. Dr. Srivastava is in the editorial board of several journals and ad-hoc reviewer of numerous scientific journals including Cancer Research, Carcinogenesis, Neoplasia and Molecular Pharmacology and also member of the study section of the National Institute of Health (NIH), Department of Defense and Susan G. Komen Breast Cancer Foundation. Dr. Srivastava has been recipient of several awards including TTUHSC “President’s Excellence in Research Award”. His research work has been featured by news agencies including BBC, MSNBC, CBS, ABC, Science News etc. and can be obtained from the following: BBC News-Pancreatic Cancer.

Research Interest

The molecular mechanisms of chemotherapeutic agents of natural origin against pancreatic, ovarian, and breast cancers. The long term goals of Dr. Srivastava’s research program are to: Identify novel dietary or synthetic chemo preventive agents, Understand their mechanism of action at the cellular and molecular level, Explore their efficacy in vivo in preclinical experiments with suitable animal models and to verify changes in surrogate biomarkers, Investigate the synergistic effects of dietary agents with chemotherapeutic agents against cancer cells, Use the information obtained in preclinical studies to design and conduct phase I clinical trials, Establish pharmacokinetic data for the anticancer agents in humans, which will help to optimize further phase II/III chemoprevention trials.